These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
399 related articles for article (PubMed ID: 26509228)
1. TAS-102 for the treatment of metastatic colorectal cancer. Salvatore L; Rossini D; Moretto R; Cremolini C; Schirripa M; Antoniotti C; Marmorino F; Loupakis F; Falcone A; Masi G Expert Rev Anticancer Ther; 2015; 15(11):1283-92. PubMed ID: 26509228 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial. Longo-Muñoz F; Argiles G; Tabernero J; Cervantes A; Gravalos C; Pericay C; Gil-Calle S; Mizuguchi H; Carrato-Mena A; Limón ML; Garcia-Carbonero R Clin Transl Oncol; 2017 Feb; 19(2):227-235. PubMed ID: 27443414 [TBL] [Abstract][Full Text] [Related]
3. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective. Chan BM; Hochster HS; Lenz HJ Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848 [TBL] [Abstract][Full Text] [Related]
5. A novel antimetabolite: TAS-102 for metastatic colorectal cancer. Miyamoto Y; Lenz HJ; Baba H Expert Rev Clin Pharmacol; 2016; 9(3):355-65. PubMed ID: 26677869 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts. Nukatsuka M; Nakagawa F; Takechi T Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349 [TBL] [Abstract][Full Text] [Related]
7. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. Kasi PM; Kotani D; Cecchini M; Shitara K; Ohtsu A; Ramanathan RK; Hochster HS; Grothey A; Yoshino T BMC Cancer; 2016 Jul; 16():467. PubMed ID: 27412464 [TBL] [Abstract][Full Text] [Related]
9. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands. Kwakman JJM; Vink G; Vestjens JH; Beerepoot LV; de Groot JW; Jansen RL; Opdam FL; Boot H; Creemers GJ; van Rooijen JM; Los M; Vulink AJE; Schut H; van Meerten E; Baars A; Hamberg P; Kapiteijn E; Sommeijer DW; Punt CJA; Koopman M Int J Clin Oncol; 2018 Jun; 23(3):482-489. PubMed ID: 29204933 [TBL] [Abstract][Full Text] [Related]
10. Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison. Masuishi T; Taniguchi H; Hamauchi S; Komori A; Kito Y; Narita Y; Tsushima T; Ishihara M; Todaka A; Tanaka T; Yokota T; Kadowaki S; Machida N; Ura T; Fukutomi A; Ando M; Onozawa Y; Tajika M; Yasui H; Muro K; Mori K; Yamazaki K Clin Colorectal Cancer; 2017 Jun; 16(2):e15-e22. PubMed ID: 27670892 [TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution. Kotani D; Shitara K; Kawazoe A; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T Clin Colorectal Cancer; 2016 Sep; 15(3):e109-15. PubMed ID: 26723516 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer. Arita S; Shirakawa T; Matsushita Y; Shimokawa HK; Hirano G; Makiyama A; Shibata Y; Tamura S; Esaki T; Mitsugi K; Ariyama H; Kusaba H; Akashi K; Baba E Anticancer Res; 2016 Apr; 36(4):1959-66. PubMed ID: 27069187 [TBL] [Abstract][Full Text] [Related]
13. TAS-102: a novel antimetabolite for the 21st century. Uboha N; Hochster HS Future Oncol; 2016 Jan; 12(2):153-63. PubMed ID: 26616466 [TBL] [Abstract][Full Text] [Related]
14. Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102). Lee JJ; Chu E Clin Colorectal Cancer; 2017 Jun; 16(2):85-92. PubMed ID: 28242161 [TBL] [Abstract][Full Text] [Related]
15. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer. Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856 [TBL] [Abstract][Full Text] [Related]
16. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Pfeiffer P; Yilmaz M; Möller S; Zitnjak D; Krogh M; Petersen LN; Poulsen LØ; Winther SB; Thomsen KG; Qvortrup C Lancet Oncol; 2020 Mar; 21(3):412-420. PubMed ID: 31999946 [TBL] [Abstract][Full Text] [Related]
18. TAS-102 (Lonsurf) for the Treatment of Metastatic Colorectal Cancer. A Concise Review. Zaniboni A; Bertocchi P; Barni S; Petrelli F Clin Colorectal Cancer; 2016 Dec; 15(4):292-297. PubMed ID: 27431756 [TBL] [Abstract][Full Text] [Related]
19. TAS-102 for Treatment of Advanced Colorectal Cancers That Are No Longer Responding to Other Therapies. van der Velden DL; Opdam FL; Voest EE Clin Cancer Res; 2016 Jun; 22(12):2835-9. PubMed ID: 27126991 [TBL] [Abstract][Full Text] [Related]
20. Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer. Zhang J; Yang W; Liu J; Wang N; Ren Z; Yang T; Xie G; Wu G; Sun Y Invest New Drugs; 2024 Aug; 42(4):454-461. PubMed ID: 38990451 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]